Among patients receiving semaglutide for obesity management, the risk for muscle loss may be higher in older adults and women ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...

There’s a perception that Ozempic, Wegovy and Zepbound are all you need to live a healthier life. But diet and exercise still ...

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...